Compositions for the treatment of blepharitis

Abstract

Embodiments relate to a method for treatment of blepharitis in a patient in need thereof comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically effective amount of at least one cannabinoid, via the topical route. Optionally, the pharmaceutical composition is administered in combination with an additional agent selected from the group consisting of: an essential oil, a steroid, an antibiotic, an anti-parasitic, a disinfectant, an anesthetic, a terpene, a moisturizer and a vitamin.

1 . A method for treatment of blepharitis in a patient in need thereof comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically effective amount of at least one cannabinoid, via the topical route. 
     
     
         2 . The method of  claim 1 , wherein the cannabinoid is selected from the group consisting of one of, or a combination of more than one of: tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannadibivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabielsoin (CBE) and cannabicitran (CBT). 
     
     
         3 . The method according to  claim 2  wherein the cannabinoid is CBD. 
     
     
         4 . The method according to  claim 1  wherein the composition comprises an oil based carrier selected from the group consisting of: benzyl alcohol, cetyl alcohol, diglycol stearate, glyceryl monostearate, liquid paraffin, light liquid paraffin, white soft paraffin, petrolatum, white paraffin, coconut oil, avocado oil, sesame oil, almond oil, olive oil, soy oil and cashew oil. 
     
     
         5 . The method according to  claim 4  wherein the composition comprises between 70% and 90% oil based carrier. 
     
     
         6 . The method according to  claim 1  wherein the pharmaceutical composition is administered in combination with an additional agent selected from the group consisting of: an essential oil, a steroid, an antibiotic, an anti-parasitic, a disinfectant, an anesthetic, a terpene, a moisturizer and a vitamin. 
     
     
         7 . The method according to  claim 6  wherein the essential oil is selected from the group consisting of: neem oil, tea tree oil, clove oil, cedarwood oil, lemon oil, and sweet orange oil. 
     
     
         8 . The method according to  claim 6  wherein the steroid is dexamethasone, loteprednol, or a pharmaceutically acceptable salt of the steroid. 
     
     
         9 . The method according to  claim 6  wherein the antibiotic is polymyxin b, neomycin, tobramycin, erythromycin, or doxycycline. 
     
     
         10 . The method according to  claim 6  wherein the anesthetic is selected from the group consisting of: lidocaine, amethocaine, proparacaine, tetracaine, and pharmaceutically acceptable salts thereof. 
     
     
         11 . The method according to  claim 6  wherein the vitamin is selected from the group consisting of vitamin A, vitamin C, and vitamin E. 
     
     
         12 . The method according to  claim 6  wherein the terpene is anti-parasitic terpinen-4-ol, α-terpinene, γ-tem ne, α-terpineol, terpinolene, p-cimene, sabinene or α-pinene. 
     
     
         13 . The method according to  claim 1  wherein the composition is applied to a surface of an eyelid of the subject and remains on the surface of the eyelid for at least 30 minutes. 
     
     
         14 . The method according to  claim 1  wherein the composition is in the form of an ointment, a cream, a lotion, a gel, or a foam. 
     
     
         15 . The method according to  claim 1  wherein the blepharitis is seborrheic, staphylococcal, mixed, posterior, meibomitis, meibomian gland dysfunction or parasitic demodex blepharitis and evaporative tear eye dysfunction (dry eye) 
     
     
         16 . The method according to  claim 1  wherein the composition comprises between 0.1% and 10% by weight of cannabinoid. 
     
     
         17 . The method according to  claim 1  wherein the composition is applied to the eyelid margin and eyelashes. 
     
     
         18 . The method according to  claim 17  wherein the composition is applied in an amount of between 0.1 g and 0.3 g per eyelid. 
     
     
         19 . The method according to  claim 1  wherein the composition is applied between twice and four times daily. 
     
     
         20 . The method according to  claim 1  wherein the composition is applied using a cloth, a disposable wipe, a sponge, a brush or a cotton-tipped applicator.